Table 1.
Baseline Characteristics
| GioTag (n = 50) | UpSwinG (n = 118) | Total (N = 168) | |
|---|---|---|---|
| Median age (years, range) | 60.5 (35–78) | 62.0 (35–88) | 61.5 (35–88) |
| Female (n, %) | 33 (66.0) | 64 (54.2) | 97 (57.7) |
| Brain metastases (at start of afatinib) (n, %) | |||
| Yes | 8 (16.0) | 20 (16.9) | 28 (16.7) |
| No | 42 (84.0) | 96 (81.4) | 138 (82.1) |
| Unknown | 0 | 2 (1.7) | 2 (1.2) |
| Brain metastases (at start of osimertinib) (n, %) | 10 (20.0) | 14 (11.9) | 24 (14.3) |
| ECOG PS (at start of afatinib) (n, %) | |||
| 0 | 16 (32.0) | 26 (22.0) | 42 (25.0) |
| 1 | 29 (58.0) | 60 (50.8) | 89 (53.0) |
| ≥2 | 3 (6.0) | 10 (8.5) | 13 (7.7) |
| Unknown | 2 (4.0) | 22 (18.6) | 24 (14.3) |
| ECOG PS (at start of osimertinib) (n, %) | |||
| 0 | 13 (26.0) | 18 (15.3) | 31 (18.5) |
| 1 | 28 (56.0) | 59 (50.0) | 87 (51.8) |
| ≥2 | 6 (12.0) | 19 (16.1) | 25 (14.9) |
| Unknown | 3 (6.0) | 22 (18.6) | 25 (14.9) |
| Mutation type (n, %) | |||
| Del19 | 31 (62.0) | 78 (66.1) | 109 (64.9) |
| L858R | 19 (38.0) | 40 (33.8) | 59 (35.1) |
| Starting dose of afatinib (mg) | |||
| <40 | 4 (8.0) | 16 (13.6) | 20 (11.9) |
| 40 | 46 (92.0) | 101 (85.6) | 147 (87.5) |
| 50 | 0 | 1 (0.8) | 1 (0.6) |
| Starting dose of osimertinib (mg) | |||
| 60 | 1 (2.0) | 0 | 1 (0.6) |
| 80 | 49 (98.0) | 118 (100.0) | 167 (99.4) |
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.